1 410

Cited 0 times in

Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer

 Seungmin Bang  ;  Han-Soo Kim  ;  Yee Shin Choo  ;  Seung Woo Park  ;  Jae Bock Chung  ;  Si Young Song 
 PANCREAS, Vol.32(1) : 29-36, 2006 
Journal Title
Issue Date
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Cisplatin/administration & dosage ; Cytotoxicity, Immunologic ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Female ; Humans ; Immunity, Cellular* ; Interleukin-10/blood ; Killer Cells, Natural/immunology* ; Male ; Middle Aged ; Neoplasm Staging ; Pancreatic Neoplasms/drug therapy* ; Pancreatic Neoplasms/immunology* ; Pancreatic Neoplasms/pathology ; Reference Values ; Vascular Endothelial Growth Factor A/blood
cell-mediated immunity ; chemotherapy ; dendritic cell ; immunotherapy ; pancreatic cancer
OBJECTIVES: Little is known about the effects of chemotherapy on the immunity of cancer patient or the ideal timing for immunotherapy combined with chemotherapy. To address these questions, we evaluated the effect of gemcitabine and cisplatin combination chemotherapy on the immunity of pancreatic cancer patients. METHODS: Thirteen patients with far advanced pancreatic cancer were enrolled and 7 sex- and age-matched healthy volunteers were included as a control group. RESULTS: Compared with healthy controls, the amounts of peripheral blood mononuclear cells, dendritic cells (DCs), natural killer cells, CD4, and CD8 T cells were reduced. With this numerical suppression, NK cell cytotoxicity to K562 leukemia cells was also significantly impaired (7.7% +/- 4.9% versus 21.7% +/- 7.9% of DNA loss; P = 0.016). Serum concentrations of VEGF and interleukin-10 (IL-10) were higher than the control group (192.1 +/- 114.7 versus 50.8 +/- 39.5 pg/mL of vascular endothelial growth factor (VEGF) and 122 +/- 68.9 versus 111.4 +/- 37.4 pg/mL of IL-10). After 1 cycle of gemcitabine and cisplatin chemotherapy, the impaired immunity of patients with pancreatic cancer was restored. Specifically, the recovery of DCs occurred rapidly and exceeded the value of healthy controls. Levels of the immunosuppressive cytokines, IL-10 and VEGF, gradually decreased during chemotherapy. CONCLUSIONS: Systemic chemotherapy seems to be beneficial for restoring the impaired immunity of patients with pancreatic cancer, and one of the ideal times to collect DCs for immunotherapy is after completing each cycle of chemotherapy.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Han Soo(김한수)
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Chung, Jae Bock(정재복)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.